On Friday, Following U.S. Stocks were among the “Top Losers”: Walter Energy, Inc. (NYSE:WLT), CTI BioPharma Corp. (NASDAQ:CTIC), Aéropostale, Inc. (NYSE:ARO)
Walter Energy, Inc (NYSE:WLT), with shares declined -27.20%, closed at $0.335.
CTI BioPharma Corp (NASDAQ:CTIC), with shares dropped -24.43%, settled at $1.97.
Aeropostale Inc (NYSE:ARO), plummeted -17.30%, and closed at $3.06.
Latest NEWS regarding these Stocks are depicted underneath:
Walter Energy, Inc. (NYSE:WLT)
On March 9, Walter Energy, Inc. (WLT), filed SEC form 8-K, regarding change in directors or principal officers.
On March 4, 2015, Graham Mascall notified Walter Energy, Inc. of his decision not to stand for re-election as a member of the Corporation’s Board of Directors at the Annual Meeting of Stockholders of the Corporation to be held on April 23, 2015. Mr. Mascall’s decision was not due to any disagreement with the Corporation on any matter regarding the Corporation’s operations, policies or practices.
Walter Energy, Inc. produces and exports metallurgical coal for the steel industry. It operates through two segments, U.S. Operations, and Canadian and U.K.
CTI BioPharma Corp. (NASDAQ:CTIC)
CTI BioPharma Corp. (CTIC), stated financial results for the fourth quarter and full year ended December 31, 2014.
Fourth Quarter and Full Year Financial Results:
Total proceeds for the fourth quarter and the full year ended December 31, 2014, were $17.8 million and $60.1 million, respectively, contrast to $32.9 million and $34.7 million for the same periods in 2013. For the fourth quarter and full year 2014, net product proceeds of PIXUVRI were $2.5 million and $6.9 million, respectively, contrast to $0.5 million and $2.3 million for the same periods in 2013. Total proceeds for the full year 2014 comprised of license and contract proceed of $53.2 million, which was primarily attributed to the following: $20.0 million development milestone payment received from Baxter for completion of enrollment in the PERSIST-1 Phase 3 clinical trial of pacritinib, recognition of $17.3 million from an upfront payment under the PIXUVRI partnership contract with Servier and $15.0 million in sales milestones related to TRISENOX®(arsenic trioxide) from Teva Pharmaceutical Industries Ltd. The decrease in fourth quarter 2014 license and contract proceeds contrast to the same period in 2013 relates to an upfront payment from Baxter upon entering into a license and partnership contract for pacritinib in 2013.
The non-GAAP operating loss, which excludes non-cash share-based compensation expense, for the fourth quarter of 2014 was $36.2 million, contrast to non-GAAP operating revenue of $13.1 million for the same period in 2013. The GAAP operating loss for the fourth quarter of 2014 was $39.4 million, contrast to a GAAP operating revenue of $10.3 million for the same period in 2013. The rise in operating loss for the fourth quarter 2014 contrast to the same period in 2013 was primarily due to the attained in process research and development associated with the attainment of certain assets related to tosedostat from Chroma in 2014 in addition to the upfront payment received from BAXTER in 2013. For the full year ended December 31, 2014, the non-GAAP operating loss was $66.0 million, contrast to $32.5 million for the same period in 2013. For the full year ended December 31, 2014, the GAAP operating loss was $86.2 million, contrast to $41.5 million for the same period in 2013. Non-cash share-based compensation expense for the fourth quarter and full year 2014 was $3.2 million and $20.2 million, respectively, contrast to $2.7 million and $9.1 million for the same periods in 2013. For information on CTI BioPharma’s use of the aforementioned non-GAAP measure and a reconciliation of such measure to GAAP operating loss, see the section below entitled “Non-GAAP Financial Measures.”
Net loss for the fourth quarter 2014 was $44.2 million, or $0.27 per share, contrast to a net revenue of $10.2 million, or $0.08 per share, for the same period in 2013. Net loss for the full year 2014 was $96.0 million, or $0.65 per share, contrast to $49.6 million, or $0.43 per share, for the same period in 2013.
As of December 31, 2014, cash and cash equivalents totaled $70.9 million, contrast to $71.6 million as of December 31, 2013.
CTI BioPharma Corp. (CTIC), is a biopharmaceutical corporation focused on the attainment, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.
Aéropostale, Inc. (NYSE:ARO)
Aéropostale, Inc. (ARO), stated results for the fourth quarter and fiscal 2014, and offered guidance for the first quarter of fiscal 2015.
Full Fiscal Year Performance:
Net sales for fiscal 2014 reduced 12% to $1.839 billion, from $2.091 billion in the year ago period. Fiscal 2014 comparable sales, counting the e-commerce channel, reduced 11% contrast to a 15% decrease for the corresponding period of the preceding year.
The Corporation stated a net loss for fiscal 2014 of $206.5 million, or $2.62 per diluted share, which comprised of:
- after-tax charges of $70.9 million, or $0.90 per diluted share resulting from store asset impairment charges, $29.1 million of which related to the Corporation’s formerly declared planned initiatives involving its P.S. from Aeropostale business;
- after-tax restructuring charges of $7.6 million or $0.10 per share related to the Corporation’s formerly declared planned initiatives;
- an after-tax charge of $5.5 million, or $0.07 per diluted share, resulting from net lease costs for closed Aeropostale and P.S. from Aeropostale stores;
- an after-tax charge of $5.0 million, or $0.06 per diluted share, related to consulting fees for planned initiatives;
- an after-tax charge of $3.4 million or $0.04 per share for the establishment of reserves against deferred tax assets;
- the above mentioned net after-tax charge of $0.5 million, or $0.01 per diluted share resulting from an intangible asset impairment related to the GoJane trademark, partially offset by the reversal of a portion of the GoJane contingent consideration liability;
- and other after-tax charges of $1.6 million, or $0.02 per diluted share for net severance.
Not taking into account these items, the adjusted net loss for fiscal 2014 was $112.0 million, or $1.42 per diluted share, for fiscal 2014.
The Corporation stated an operating loss for fiscal 2014 of $213.1 million or, not including the aforementioned charges, an operating loss of $113.4 million.
The Corporation ended the year with cash and cash equivalents of $151.8 million and long-term debt of $138.5 million. As of January 31, 2015, the Corporation had no borrowings outstanding and availability of $116.8 million under its revolving credit facility.
Aeropostale®, Inc. is a primarily mall-based, specialty retailer of casual apparel and accessories, principally targeting 14 to 17 year-old young women and men through its Aeropostale® stores and 4 to 12 year-olds through its P.S. from Aeropostale® stores. The Corporation provides customers with a focused selection of high quality fashion and fashion basic merchandise at compelling values in an exciting store environment.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
